Siklofosfamid ile indüklenen testiküler hasarda silimarinin koruyucu ve tedavi edici etkisinin araştırılması
Küçük Resim Yok
Tarih
2024
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Düzce Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Giriş ve amaç: Deve dikeni (Silybum marianum) bitkisinden elde edilen bir flavanoid olan silimarin serbest oksijen radikallerinden koruyan kuvvetli bir antioksidan maddedir. İnsan ve hayvan modellerinde bu maddenin antioksidan, anti-enflamatuvar etkileri gösterilmiştir. Siklofosfamid (CYP) alkilleyici ilaçlar grubunda yer alan, immünsüpresan ve kanser önleyici bir ilaçtır. CYP rejimleri alan erkeklerde testiküler atrofi, infertilite ve azospermi insidansının arttığı gösterilmiştir. Bu çalışmadaki amacımız ratlarda siklofosfamidle indüklenen testiküler hasar modelinde silimarinin testiküler dokuda koruyucu ve tedavi edici etkilerini biyokimyasal belirteçler ve histopatolojik sonuçlar açısından araştırmaktır. Gereç ve yöntem: Bu çalışmada toplam 47 Wistar-Albino ırkı erkek rat kullanıldı. Kontrol grubunda 5, diğer deney gruplarında her biri 7 adet olacak şekilde (1 kontrol ve 6 deney grubu) planlama yapıldı. Deneyde siklofosfamid tek doz intraperitoneal ve silimarin (SMN) günde 2 defa oral gavaj ile verildi. Denekler 14. günün sonunda sakrifiye edildi. Serum folikül stimüle edici hormon (FSH), luteinize edici hormon (LH), testosteron, total antiksidan kapasite (TAS), total oksidatif kapasite (TOS), malondialdehit (MDA) aktivitesi ölçümleri yapıldı. Sağ testis histopatolojik inceleme için, sol testis TAS, TOS, MDA aktivitesi ölçümü için kullanıldı. Histolojik inceleme için Hematoksilen-Eozin, Gomori Trikrom boyama yapıldı. Johnsen skorlamasıyla testiküler hasar değerlendirildi. Bulgular: Yapılan analiz sonuçlarına göre testis ağırlıkları, ağırlık indeksi ve hacimlerinde gruplar arasında anlamlı fark izlenmedi. Deneklerin ağırlık değişimlerine bakıldığında SMN koruyucu olarak verildiğinde kilo değişimini anlamlı ölçüde azalttığı ancak normal seviyeye çıkaramadığı görüldü. SMN' nin koruyucu ve tedavi edici olarak kullanımının oksidatif stres indeksini anlamlı düzeyde düşürdüğü izlendi. Serum ve doku MDA düzeylerinde anlamlı farklılık izlenmedi. Silimarinin hormonal dengeyi korumada etkin olduğu görülmüştür. Sonuç: Çalışmamızda silimarin siklofosfamidin neden olduğu testiküler hasarda histopatolojik ve biyokimyasal iyileşme sağlamıştır. Ayrıca testiküler hasarı önlemede silimarinin tedavi edici etkisinin, koruyucu etkisine göre daha güçlü olduğu ve artan dozlarla iyileşme oranının da arttığı görülmüştür. Gelecekte yapılacak randomize prospektif çalışmalar, silimarinin testis hasarında özellikle fertilitenin korunması ve tedavisi için kullanımı açısından yol gösterici olacaktır.
Introduction and objective: Silymarin, a flavonoid derived from the plant milk thistle (Silybum marianum), is a potent antioxidant that protects against free oxygen radicals. Its antioxidant and anti-inflammatory effects have been demonstrated in both human and animal models. Cyclophosphamide (CYP), a member of the alkylating agents group, is an immunosuppressive and anticancer drug. It has been shown that men undergoing CYP regimens experience increased incidence of testicular atrophy, infertility, and azoospermia. The aim of this study is to investigate the protective and therapeutic effects of silymarin on testicular tissue in a cyclophosphamide-induced testicular damage model in rats, using biochemical markers and histopathological outcomes. Materials and Methods: A total of 47 male Wistar-Albino rats were used in this study. The study was planned with one control group consisting of 5 rats and six experimental groups, each comprising 7 rats. Cyclophosphamide was administered as a single intraperitoneal dose, while silymarin (SMN) was given twice daily via oral gavage. At the end of day 14, the rats were sacrificed. Measurements included serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, total antioxidant capacity (TAS), total oxidative capacity (TOS), and malondialdehyde (MDA) activity. The right testis was used for histopathological examination, while the left testis was used for TAS, TOS, and MDA activity measurements. For histological analysis, Hematoxylin-Eosin and Gomori Trichrome staining were performed. Testicular damage was evaluated using Johnsen's scoring system. Results: According to the analysis results, no significant differences were observed between the groups in testicular weight, weight index, and volume. Regarding weight changes in the subjects, it was noted that silymarin (SMN), when administered as a protective agent, significantly reduced weight loss but did not restore it to normal levels. The use of SMN as both a protective and therapeutic agent was found to significantly reduce the oxidative stress index. No significant differences were observed in serum and tissue malondialdehyde (MDA) levels. Silymarin was shown to be effective in maintaining hormonal balance. Conclusion: Our study demonstrated that silymarin provided histopathological and biochemical improvement in cyclophosphamide-induced testicular damage. Furthermore, the therapeutic effect of silymarin in preventing testicular damage was found to be more potent than its protective effect, with higher doses correlating with an increased rate of recovery. Future randomized prospective studies will be instrumental in guiding the use of silymarin for the prevention and treatment of testicular damage, particularly in preserving fertility..
Introduction and objective: Silymarin, a flavonoid derived from the plant milk thistle (Silybum marianum), is a potent antioxidant that protects against free oxygen radicals. Its antioxidant and anti-inflammatory effects have been demonstrated in both human and animal models. Cyclophosphamide (CYP), a member of the alkylating agents group, is an immunosuppressive and anticancer drug. It has been shown that men undergoing CYP regimens experience increased incidence of testicular atrophy, infertility, and azoospermia. The aim of this study is to investigate the protective and therapeutic effects of silymarin on testicular tissue in a cyclophosphamide-induced testicular damage model in rats, using biochemical markers and histopathological outcomes. Materials and Methods: A total of 47 male Wistar-Albino rats were used in this study. The study was planned with one control group consisting of 5 rats and six experimental groups, each comprising 7 rats. Cyclophosphamide was administered as a single intraperitoneal dose, while silymarin (SMN) was given twice daily via oral gavage. At the end of day 14, the rats were sacrificed. Measurements included serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone, total antioxidant capacity (TAS), total oxidative capacity (TOS), and malondialdehyde (MDA) activity. The right testis was used for histopathological examination, while the left testis was used for TAS, TOS, and MDA activity measurements. For histological analysis, Hematoxylin-Eosin and Gomori Trichrome staining were performed. Testicular damage was evaluated using Johnsen's scoring system. Results: According to the analysis results, no significant differences were observed between the groups in testicular weight, weight index, and volume. Regarding weight changes in the subjects, it was noted that silymarin (SMN), when administered as a protective agent, significantly reduced weight loss but did not restore it to normal levels. The use of SMN as both a protective and therapeutic agent was found to significantly reduce the oxidative stress index. No significant differences were observed in serum and tissue malondialdehyde (MDA) levels. Silymarin was shown to be effective in maintaining hormonal balance. Conclusion: Our study demonstrated that silymarin provided histopathological and biochemical improvement in cyclophosphamide-induced testicular damage. Furthermore, the therapeutic effect of silymarin in preventing testicular damage was found to be more potent than its protective effect, with higher doses correlating with an increased rate of recovery. Future randomized prospective studies will be instrumental in guiding the use of silymarin for the prevention and treatment of testicular damage, particularly in preserving fertility..
Açıklama
Anahtar Kelimeler
Üroloji, Urology, Siklofosfamid, silimarin, testiküler hasar, Cyclophosphamide, silymarin, testicular damage
